News Summary

Life Biosciences, a longevity startup based in Boston, has initiated human trials for its ER-100 drug, aiming to reverse age-related sight loss. This groundbreaking trial marks the first time cellular-rejuvenation therapy using this technology has received FDA clearance for human clinical trials. The study will involve approximately 18 adults over the next year, focusing on patients with glaucoma and NAION, conditions affecting the optic nerve. The ER-100 drug is designed to rejuvenate cells in the optic nerve to restore vision, a significant step in longevity science. Cofounder David Sinclair, a Harvard Medical School genetics professor, emphasizes the potential of this technology to reverse cellular aging and tackle various age-related diseases.